Batu Biologics Recruits Cancer Immunologist to Scientific Advisory Board

Collaboration of IND-enabling experiments for ValloVax™ with Dr. Fang November 19, 2014 Batu Biologics, an immunotherapy company working to develop ValloVax, an anti-angiogenic cancer vaccine, announced today the addition of Dr. Deyu Fang to its Scientific Advisory Board. Deyu Fang, Ph.D. is an immunologist and associate professor working in the Department of Pathology at Northwestern University Feinberg School of Medicine. …

Batu Biologics Achieves Goal in Successful Crowdfunding Campaign

Biotech Startup Aims for FDA Approval for Novel Anti-Angiogenic Cancer Vaccine August 18th, 2014 Using a fundraising approach seldom seen in the life sciences sector, Batu Biologics, an immunotherapy company working to develop the first anti-angiogenic cancer vaccine, has successfully raised $100,000 through the Indiegogo crowdfunding platform. Batu Biologics launched the crowdfunding campaign in June 2014 to fund the completion …

Batu Biologics Strategy for FDA Approval of Lung Cancer Immunotherapy Featured in San Diego Business Journal

July 27th, 2014 Batu Biologics announced today that it’s President and CEO, Samuel C. Wagner, was featured in the weekly business publication, the San Diego Business Journal. The article, which was published in the July 21st edition, discussed the company’s strategy in developing its immunotherapeutic lung cancer vaccine, ValloVax, for which FDA Investigational New Drug (IND) submission is planned in Q1 …

Batu Biologics Appoints Biotechnology Industry Veteran, Dr. Alan Lewis, to Scientific Advisory Board

Former CEO of Medistem to Assist in the FDA Development of the First Anti-Angiogenic Cancer Vaccine for Lung Cancer June 2, 2014 Batu Biologics announced today the appointment of Dr. Alan Lewis to the company’s Scientific Advisory Board, an experienced industry veteran with over 37 years of experience as an executive in life sciences. Dr. Lewis spent 15 years at …

Batu Biologics Launches Crowdfunding Campaign to Complete Preclinical Testing for Vallovax Cancer Therapy

San Diego immunotherapy company seeks to raise $100,000 to complete IND enabling experiments for the FDA June 18, 2014 Batu Biologics announced today the launch of its first crowdfunding campaign with Indiegogo seeking to raise $100,000 dollars to complete preclinical testing for Vallovax, an immunotherapeutic product which selectively kills blood vessels feeding the tumor. Individuals seeking to contribute may do …

Batu Biologics Announces FDA Development Plans for ValloVax™ Angiogenesis-Targeting Cancer Vaccine

Company Plans to Develop “Next Generation” Govallo Cancer Vaccine, VG-1000, for American Population June 9, 2014 Batu Biologics announced today FDA development plans for its patent-pending lead product, ValloVax™, a cancer immunotherapeutic “vaccine” that specifically targets the tumor blood vessels (endothelium). The vaccine is a “therapeutic vaccine” in that it will be used to stimulate the immune system of patients …

Batu Biologics Files Patent Covering its Proprietary Cancer Vaccine Targeting the Tumor Endothelium: Vallovax

Animal Studies Demonstrate Efficacy in Treatment of Non-Small Cell Lung Cancer May 23, 2014 Batu Biologics, a biopharmaceutical company focused on the development and commercialization of cell therapies in the area of immune modulation, is pleased to announce the filing of U.S. patent application (61/987657) covering the composition and application of its flagship product, Vallovax. The novel cancer vaccine is …